Burford takes aim at opioid overdose medication in series of IPRs
Reviews challenge validity of patents owned by Opiant Pharmaceuticals relating to Narcan brand of naloxone as price of treatments rises
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.